Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Transcript of the Investors'' Conference Call for the quarter ended June 30, 2023 Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Audio recording of investor conference call
Jubilant Ingrevia Results Earnings Call for Q1FY24
Conference Call with Jubilant Ingrevia Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript. Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of Copies of published Unaudited Standalone and Consolidated Financial Results Jubilant Ingrevia Ltd - 543271 - Jubilant Ingrevia Employees Stock Option Plan 2021
Pursuant to Regulation 30 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that NRC Committee held at its meeting held on July 26, 2023, has granted stock options as mentioned in intimation letter attached. Q1FY24 Quarterly Result Announced for Jubilant Ingrevia Ltd.
Specialty chemicals company Jubilant Ingrevia announced Q1FY24 results: Q1FY24 vs Q1FY23: Total revenue: Rs 1,075 crore vs Rs 1,166 crore, down 8% YoY Total EBITDA: Rs 125 crore vs Rs 151 crore, down 17% YoY EBITDA margin (%): 11.6% vs 12.9% Profit after tax: Rs 58 crore vs Rs 79 crore, down 27% YoY Profit after tax margin (%): 6.8% vs 5.4% Basic & diluted EPS: Rs 3.6 vs Rs 5, down 27% YoY Commenting on the Company’s performance, Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman, Jubilant Ingrevia, said: “We are pleased to announce stable performance in Q1FY24, given the backdrop of depressed market conditions specifically in Agrochemical end-use markets. In our specialty chemicals business, demand from our agrochemical customers globally continues to face headwinds due to exceptionally higher pipeline inventories. However, demand from our Pharmaceutical and other customers has improved leading to improved price realization and margins from these products including CDMO. In our Nutrition & Health Solution Business, Niacinamide sales volumes improved significantly, resulting into revenue growth. We continue to witness improved price realisation due to higher demand in the segment. Businesses continue to maintain the global leadership position in Niacinamide and focus on Niche segments like Food & Cosmetics. In our Chemical Intermediates Business, we continue to improve our market share of key product Acetic Anhydride, despite the challenges of lower demand from the agrochemical end-use segment. We also witnessed lower price realisation in the segment due to pricing pressure from the agro end-use of Acetic Anhydride and lower realisation of Ethyl Acetate in the export market. We are witnessing softening of coal prices and with that, our overall energy cost is expected to normalise. We remain committed towards our growth plans and are confident that our well-defined capex plan will deliver structured growth in the future as planned.” Result PDF Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release for quarter ended June 30, 2023 is attached in the intimation letter. Jubilant Ingrevia Ltd - 543271 - Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of CEO & Managing Director Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Change in Directorate
Superannuation of Managing Director